Results 111 to 120 of about 561,014 (300)

Follicle-Stimulating Hormone Exacerbates Cardiovascular Disease in the Presence of Low or Castrate Testosterone Levels

JACC: Basic to Translational Science
Summary: Low testosterone (T), common in aging men, associates with cardiovascular disease. We investigated whether follicle-stimulating hormone (FSH), which is affected by T, modulates the cardiovascular effects associated with low T or castration. FSHβ−
Wilhelmina C.M. Duivenvoorden, MSc PhD, David Margel, MD, PhD, Vishal Subramony Gayathri, MSc, Emmanuelle Duceppe, MD, PhD, Sadiya Yousef, BSc, Magda Naeim, PhD, Mohammad Khajehei, MSc, Sarah Hopmans, MSc, Snezana Popovic, MD, Yaara Ber, MSc, Diane Heels-Ansdell, MSc, Philip J. Devereaux, MD, PhD, Jehonathan H. Pinthus, MD, PhD   +12 more
doaj   +1 more source

Efficacy and safety of oral gonadotropin-releasing hormone antagonists in moderate-to-severe endometriosis-associated pain: a systematic review and network meta-analysis. [PDF]

Arch Gynecol Obstet, 2023
Xin L, Ma Y, Ye M, Chen L, Liu F, Hou Q.
europepmc   +1 more source

Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up

, 2011
Increasing evidence supports GnRH agonists to be an effective treatment to preserve ovarian function during chemotherapy, but the initial flare-up of FSH during the first week after GnRH agonist application still limits its use.
Kämmerer, Ulrike, Kollmann, Zahraa, Frambach, Torsten, von Wolff, Michael, Alessandro Santi, Johannes Dietl, Santi, Alessandro, Michael von Wolff, Torsten Frambach, Dietl, Johannes, Ulrike Kämmerer, Zahraa Kollmann   +11 more
core   +1 more source

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Beyond depression and anxiety; a systematic review about the role of corticotropin-releasing hormone antagonists in diseases of the pelvic and abdominal organs. [PDF]

PLoS One, 2022
Pagán-Busigó JE, López-Carrasquillo J, Appleyard CB, Torres-Reverón A.   +3 more
europepmc   +1 more source

Regulation of the juvenile hormone titre in the Colorado potato beetle [PDF]

, 1978
Three main topics were investigated in regulation of the titre of juvenile hormone in haemolymph of the Colorado potato beetle ( Leptinotarsa decemlineata Say): enzymic breakdown of the hormone; binding and protection of the hormone by carrier proteins ...
Kramer, S.J.
core  

p190A/ARHGAP35 and p190B/ARHGAP5 proteins in endometrial cancer: a novel cancer‐relevant paralog interplay

Molecular Oncology, EarlyView.
This study identifies ARHGAP5, in addition to the frequently mutated ARHGAP35, as significantly mutated in endometrial cancer. Mutations in both genes co‐occur and are associated with their correlated downregulation. Functional CRISPR studies show that both paralogs regulate similar pathways, including actin cytoskeleton organization.
Mathilde Pinault, Capucine Heraud, Mélissa Correia de Oliveira, Véronique Neaud, Valérie Valesco, Valérie Prouzet‐Mauleon, Béatrice Turcq, Jean‐William Dupuy, Anne‐Aurélie Raymond, Sabrina Croce, Frédéric Saltel, Valérie Lagrée, Violaine Moreau   +12 more
wiley   +1 more source

Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs. [PDF]

J Cell Commun Signal, 2021
Akhter MS, Uddin MA, Schally AV, Kubra KT, Barabutis N.   +4 more
europepmc   +1 more source

Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone

, 2007
This article reviews the clinical uses of agonists and antagonists of luteinizing-hormone-releasing hormone (LHRH), also known as gonadotropin-releasing hormone.
Schally, Andrew V, Andrew V Schally, Engel, Jörg B, Jörg B Engel   +3 more
core   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source